XM does not provide services to residents of the United States of America.
E
E

Expedia

News

U.S. STOCKS IonQ, Cassava Sciences, MeridianLink

BUZZ-U.S. STOCKS ON THE MOVE-IonQ, Cassava Sciences, MeridianLink Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The blue-chip Dow rose on Friday to hit an intraday record and small-cap stocks outperformed after a benign inflation report cleared the way for the Federal Reserve to focus on shoring up the labor market while continuing its interest rate easing.
C
E
R
S
R
W
U
U
G
C
L

U.S. STOCKS Regeneron, HP Inc, Honeywell International

BUZZ-U.S. STOCKS ON THE MOVE-Regeneron, HP Inc, Honeywell International Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The blue-chip Dow rose on Friday to hit an intraday record high and small-cap stocks outperformed after a benign inflation report cleared the way for the Federal Reserve to focus on shoring up the labor market while continuing its interest rate easing.
A
C
E
L
R
S
W
W
U
U
D
C
L

BTIG says Expedia trades at 'steep discount', raises PT

BUZZ-BTIG says Expedia trades at 'steep discount', raises PT ** BTIG has raised Expedia's EXPE.O PT to $175 from $150 ** New PT represents a 17.86% upside to the stock's last close ** Shares rise ~1% at $149 premarket ** BTIG maintains "buy" citing "steep discount" at EXPE, sees it as a "better" co with higher margins ** We see EXPE as an under-app
E

U.S. Albemarle, Nasdaq, Salesforce

U.S. RESEARCH ROUNDUP-Albemarle, Nasdaq, Salesforce Sept 27 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Albemarle, Nasdaq and Salesforce, on Friday. HIGHLIGHTS * Agios Pharmaceuticals Inc AGIO.O : Leerink Partners cuts to market perform from outperform * Albemarle ALB.N : Jefferies cuts target price to $120 from $124 * Dollar General Corp DG.N : Citigroup cuts to sell from neutral * Nasdaq Inc NDAQ.O : RBC initia
A
C
C
C
D
E
N
P
S
T
D
A
C
C
U

U.S. Cintas, Nasdaq, Talen Energy

U.S. RESEARCH ROUNDUP-Cintas, Nasdaq, Talen Energy Sept 26 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cintas, Nasdaq and Talen Energy, on Thursday. HIGHLIGHTS * Celldex Therapeutics Inc CLDX.O : Wells Fargo raises to overweight from equal weight * Cintas Corp CTAS.O : JP Morgan raises target price to $228 from $212.50 * Expedia Group Inc EXPE.O : TD Cowen cuts to hold from buy * Nasdaq Inc NDAQ.O : TD Cowen init
C
C
E
M
N
F
E
G
C
F

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.